Selank guide

At a glance

What the research says

The cited clinical report compared Selank with medazepam in 62 patients with generalized anxiety disorder or neurasthenia. Thirty received Selank and 32 received the comparator. Researchers used symptom-rating scales and measured serum enkephalin activity to explore clinical and biological responses in that population.[2]

The abstract reports changes in symptom assessments and relationships with the enkephalin measure. It does not specify the administration route, so this guide does not infer one from the library's nasal or subcutaneous options. It also does not report a plasma Selank concentration-time experiment.[2][1]

A clinical response assessment cannot supply missing elimination, absorption, or bioavailability measurements. The library explicitly identifies all three model inputs as unreported in this publication. Selank's short timing value therefore remains an estimate even though the reference involves human participants rather than only laboratory experiments.[2][1]

Cited amounts

The library records 10 mg as a supplier catalog package amount. This is the total listed in that presentation, not an amount selected for administration. No personal dosing range is inferred from it.[1][3]

Half-life and timing

The 0.75-hour input corresponds to 45 minutes, giving a five-interval span of 225 minutes. One quarter remains after 90 minutes and one thirty-second after 225. The arithmetic can be reproduced exactly even though the input is authored rather than measured by the cited study. Both available recording routes use the same low-confidence estimates. The bar cannot establish route equivalence, recover an unreported bioavailability, or predict an individual concentration simply because the intervals are displayed precisely.[1][5]

Reconstitution

Suppose the 10 mg catalog amount occupied an assumed final liquid volume of 2 mL. The result would be 5 mg/mL, with 0.1 mL representing 0.5 mg. The equation concerns mass and volume only. It does not establish a delivered nasal-spray volume or a subcutaneous amount, and it cannot verify a preparation's composition. A catalog package can anchor this dimensional exercise while the human study still fails to provide the model parameters needed for a measured concentration profile.[3]

Tracking it in PinPoint

Frequently asked questions

What does a Selank vs Semax comparison show about half-life?

Both entries store 0.75 hours, but the evidence descriptions differ. Selank's cited human study does not state the model inputs, while Semax's timing context comes from rat literature. The matching numbers are not proof of matching human pharmacokinetics.[1][2]

Does Selank's human-study citation establish its 45-minute input?

The library explicitly says the citation is not a pharmacokinetic source and states none of the three model inputs. The 45-minute conversion comes from the stored estimate. It must not be relabeled as a direct result of that study.[1][5]

Are Selank's nasal and subcutaneous curves independently validated here?

The library uses the same low-confidence estimates for both recording routes. It does not supply separate measured parameter sets. A route choice in the tracker therefore cannot be interpreted as evidence that the source characterized both forms independently.[1][5]

Can a peptide tracker app record Selank?

PinPoint's compound library includes Selank. The app description covers logging compound, dose, site, and pain level, as well as viewing modeled levels between recorded doses. The curve uses published reference inputs and does not account for individual variation. The tracker records the schedule entered by its user; it does not choose a dose or recommend a schedule change.[1][4]

Sources

Facts and reference links were retrieved from the PinPoint application library on 5 October 2026. Links below preserve the library's citations; a catalog source supports a package amount only. Source references carried from the library have not all been independently reverified. Arithmetic examples are identified separately from clinical evidence.

1. PinPoint compound library, SelankSnapshot of the application library; its references and uncertainty are retained below.Retrieved 2026-10-05 · library
2. PubMed pharmacology reference 18454096Identity and research summary checked against this document on 5 October 2026. PubMed abstract, retrieved through NCBI EFetch.Retrieved 2026-10-05 · library-reference
3. Supplier catalog package referencePackage amount only; not a clinical amount or endorsement.Retrieved 2026-10-05 · supplier
4. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description
5. Unit conversion and exponential-decay arithmeticC = amount / volume; remaining fraction = 2^(-elapsed / half-life). These are illustrations, not measurements.Retrieved 2026-10-05 · arithmetic
6. PubMed Selank identity reference 18197389Opening identity checked 5 October 2026. Abstract: heptapeptide sequence and relationship to tuftsin.Retrieved 2026-10-05 · primary-reference